APTO
$4.86
Aptose Bioscns
$.24
5.19%
APTO
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.20)
Revenue:  $0.00 Mil
Tuesday
Aug 3
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, May 4, 2021

What do you expect when APTO reports earnings?
Beat
Meet
Miss

Where is APTO's stock price going from here?
Up
Flat
Down
Stock chart of APTO
Analysts
Summary of analysts' recommendations for APTO
Score
Grade
Pivots
Resistance
$5.24
$5.06
$4.96

$4.79

Support
$4.69
$4.51
$4.41
Tweet
Growth
Description
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada.
Peers
InterCeptVertex PharmaceuticalsBioMarin PharmaceuticalRegeneron PharmaceuticalsUltragenyx PharmaceuticalZoetisBristol-Myers SquibbPfizerEli LillyMerck & Co.